JNJ 0376
Alternative Names: JNJ-0376Latest Information Update: 08 May 2023
At a glance
- Originator Johnson & Johnson
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 27 Apr 2023 Phase-I clinical trials in Parkinson's disease in an unknown location (unspecified route) (Johnson & Johnson pipeline, April 2023)